PREV — Preveceutical Medical Income Statement
0.000.00%
- CA$20.54m
- CA$25.13m
Annual income statement for Preveceutical Medical, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | — | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3.36 | 1.06 | 1.2 | 0.963 | 0.812 |
| Operating Profit | -3.36 | -1.06 | -1.2 | -0.963 | -0.812 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.81 | -1.75 | -1.48 | -1.27 | -1.17 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.8 | -1.73 | -1.48 | -1.27 | -1.17 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.8 | -1.73 | -1.48 | -1.27 | -1.17 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.8 | -1.73 | -1.48 | -1.27 | -1.17 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.006 | -0.003 | -0.003 | -0.002 | -0.002 |